Details

Autor(en) / Beteiligte

• Oldham, William M.
• Hemnes, Anna R.
• Aldred, Micheala A.
• Barnard, John
• Brittain, Evan L.
• Chan, Stephen Y.
• Cheng, Feixiong
• Cho, Michael H.
• Desai, Ankit A.
• Garcia, Joe G.N.
• Geraci, Mark W.
• Ghiassian, Susan D.
• Hall, Kathryn T.
• Horn, Evelyn M.
• Jain, Mohit
• Kelly, Rachel S.
• Leopold, Jane A.
• Lindstrom, Sara
• Modena, Brian D.
• Nichols, William C.
• Rhodes, Christopher J.
• Sun, Wei
• Sweatt, Andrew J.
• Vanderpool, Rebecca R.
• Wilkins, Martin R.
• Wilmot, Beth
• Zamanian, Roham T.
• Fessel, Joshua P.
• Aggarwal, Neil R.
• Loscalzo, Joseph
• Xiao, Lei

Titel

NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification

Ist Teil von

• Journal of the American College of Cardiology, 2021-04, Vol.77 (16), p.2040-2052

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2021

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• The National Heart, Lung, and Blood Institute and the Cardiovascular Medical Research and Education Fund held a workshop on the application of pulmonary vascular disease omics data to the understanding, prevention, and treatment of pulmonary vascular disease. Experts in pulmonary vascular disease, omics, and data analytics met to identify knowledge gaps and formulate ideas for future research priorities in pulmonary vascular disease in line with National Heart, Lung, and Blood Institute Strategic Vision goals. The group identified opportunities to develop analytic approaches to multiomic datasets, to identify molecular pathways in pulmonary vascular disease pathobiology, and to link novel phenotypes to meaningful clinical outcomes. The committee suggested support for interdisciplinary research teams to develop and validate analytic methods, a national effort to coordinate biosamples and data, a consortium of preclinical investigators to expedite target evaluation and drug development, longitudinal assessment of molecular biomarkers in clinical trials, and a task force to develop a master clinical trials protocol for pulmonary vascular disease. [Display omitted] •Pulmonary hypertension can arise from a heterogeneous array of pathological processes.•Clinical, genetic, and molecular phenotyping provide data that inform new approaches to the classification of pulmonary vascular diseases.•A biomarker-based classification system can organize research and improve precision in patient evaluation and management.•Clinical advances will require the integration of novel analytic approaches, development of translational research pathways, and incorporation of biomarkers into clinical trial designs.